



Survivorship Cutaneous Melanoma

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD , services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.





Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Boland, G. M., & Gershenwald, J. E. (2015). Melanoma Survivorship Management. *In Advances in Cancer Survivorship Management* (pp. 219-239). Springer New York.
- Brown, R. E., Stromberg, A. J., Hagendoorn, L. J., Hulsewede, D. Y., Ross, M. I., Noyes, R. D., ... & McMasters, K. M. (2010). Surveillance after surgical treatment of melanoma: futility of routine chest radiography. *Surgery*, 148(4), 711-717.
- Centers for Disease Control and Prevention. (2018, March 5). *Recommended immunization schedule for adults aged 19 years or older, United States 2018*. Retrieved from <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>
- Francken, A. B., Accortt, N. A., Shaw, H. M., Colman, M. H., Wiener, M., Soong, S. J., ... & Thompson, J. F. (2008). Follow-up schedules after treatment for malignant melanoma. *British Journal of Surgery*, 95(11), 1401-1407.
- Gamble, R. G., Jensen, D., Suarez, A. L., Hanson, A. H., McLaughlin, L., Duke, J., & Dellavalle, R. P. (2010). Outpatient follow-up and secondary prevention for melanoma patients. *Cancers*, 2(2), 1178-1197.
- Garbe C, Peris K, Hauschild A, et al. (2010). Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. *European Journal of Cancer*; 46(2):270-283.
- Leiter, U., Eigentler, T. K., Forschner, A., Pflugfelder, A., Weide, B., Held, L., ... & Garbe, C. (2010). Excision guidelines and follow-up strategies in cutaneous melanoma: facts and controversies. *Clinics in dermatology*, 28(3), 311-315.
- Machet, L., Nemeth-Normand, F., Giraudeau, B., Perrinaud, A., Tiguemounine, J., Ayoub, J., ... & Lorette, G. (2005). Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. *British journal of dermatology*, 152(1), 66-70.
- Morton RL, Craig JC, Thompson JF. (2005). The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. *British journal of Dermatology*;152(1):66-70.
- NCCN Clinical Practice Guidelines in Oncology, Melanoma V1.2017. www.nccn.org [accessed: January 2017]
- Nieweg, O. E., & Kroon, B. B. (2006). The conundrum of follow-up: should it be abandoned?. *Surgical oncology clinics of North America*, 15(2), 319-330.
- Romano, E., Scordo, M., Dusza, S. W., Coit, D. G., & Chapman, P. B. (2010). Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. *Journal of Clinical Oncology*, 28(18), 3042-3047.
- Trotter, S. C., Sroa, N., Winkelmann, R. R., Olencki, T., & Bechtel, M. (2013). A Global Review of Melanoma Follow-up Guidelines. *The Journal of Clinical and Aesthetic Dermatology*, 6(9), 18-26.
- Speijers, M. J., Francken, A. B., Hoekstra-Weebers, J. E., Bastiaannet, E., Kruijff, S., & Hoekstra, H. J. (2010). Optimal follow-up for melanoma. *Expert Review of Dermatology*, 5(4), 461-478.
- Vanderbilt Cardio-Oncology Program. (2017). *Know Your ABCDE's*. Retrieved from <http://www.cardioonc.org/2017/08/29/know-your-abcs/>

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Melanoma Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Olga N. Fleckenstein[♦]
Jeffrey E. Gershenwald, MD[‡]
Paula Lewis-Patterson, DNP, RN, NEA-BC
Jeffrey N. Myers, MD
Kristen Pytynia, MD
E. Lane Read, PA-C
Merrick Ross, MD
Erich M. Sturgis, MD
Shirlene Tabao, MSN, RN, OCN[♦]
Hussein Tawbi, MD, PhD
Randal S. Weber, MD
Mark Zafereo, MD

[‡] Core Development Lead

[♦] Clinical Effectiveness Development Team